CIAM
HRTX icon

Caitong International Asset Management’s Heron Therapeutics HRTX Stock Holding History

Caitong International Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
1
– – ﹤0.01% 3196
2026
Q1 		$1 Sell
1
-35,105
-100% -$40.7K ﹤0.01% 2481
2025
Q4 		$45.6K Buy
35,106
+27,040
+335% +$33.4K 0.01% 739
2025
Q3 		$10.2K Buy
8,066
+5,885
+270% +$9.33K 0.01% 1011
2025
Q2 		$4.51K Sell
2,181
-657
-23% -$1.34K ﹤0.01% 1059
2025
Q1 		$6.24K Buy
2,838
+2,208
+350% +$4.29K ﹤0.01% 969
2024
Q4 		$964 Buy
+630
New +$1.02K ﹤0.01% 1334

Other funds holding HRTX

Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Caitong International Asset Management's HRTX Position: Q2 2026 in Review

Caitong International Asset Management held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3196.

Caitong International Asset Management first reported a position in HRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $45.6K in Q4 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Caitong International Asset Management held 1 share of Heron Therapeutics worth $0 as of Q2 2026.
  • Caitong International Asset Management left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #3196 holding.
  • Caitong International Asset Management first reported a position in Heron Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Caitong International Asset Management's Heron Therapeutics position peaked at $45.6K in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.